• Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated
  • Commercial strategy reinforced with product acquisition and upcoming commercial launch
    • Abstral® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reiterated guidance of $8-$10 million for the full year 2014
    • Zuplenz® (ondansetron) Oral Soluble Film U.S. rights licensed; launch expected in Q1 2015
  • Conference call scheduled for 5:00 pm E.T. today with details below

PORTLAND, Ore., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today reported its financial results for the quarter ended September 30, 2014 and provided a business update.

"The company continues to make excellent progress on our clinical programs, and we continue to build our commercial franchise," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "I believe we have turned the corner on the corporate challenges we faced this year, and we are fully focused on the progress of NeuVax and its portfolio of clinical trials, our development pipeline and our commercial programs including the upcoming launch of Zuplenz ®. Over the next six months, we will report results from the ongoing trials with GALE-301 and GALE-401, and our NeuVax platform will expand with the initiation of two new trials plus the completion of enrollment in our pivotal, Phase 3 PRESENT study. The launch of Zuplenz in Q1 2015 enhances our commercialization efforts and we believe we will see significant sales growth for that business line in 2015."

Galena will host a conference call today at 2:00 p.m. P.T./5:00 p.m. E.T. to discuss financial and business results. The call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 23451769. The conference call will also be webcast live and available under the Investors section/Events and Presentations on the Company's website at www.galenabiopharma.com. The archived webcast replay will be available on the Company's website for 90 days.

Financial Highlights

Net revenue for the third quarter of 2014 was $1.6 million compared to $1.2 million for the third quarter of 2013, an increase of 25%. Net revenue for the nine months ended September 30, 2014 was $6.1 million. The third quarter of 2013 was the first quarter that the company generated net revenue.

Operating loss for the three months ended September 30, 2014 was $13.2 million, including $1.3 million in stock-based compensation charges, compared to $6.9 million, including $0.5 million in stock-based compensation charges, for the three months ended September 30, 2013.

Galena also incurs non-cash income and expense related to changes in the fair value estimates of the Company's warrant liabilities. Non-cash income related to the change in warrant values for the three months ended September 30, 2014 was $6.7 million compared to non-cash expense of $1.6 million for the three months ended September 30, 2013.

Net loss for the three months ended September 30, 2014 was $6.2 million, or $0.05 per basic and diluted share, compared to a net loss of $9.3 million, or $0.11 per basic and diluted share, for the three months ended September 30, 2013.

As of September 30, 2014, Galena had cash and cash equivalents of $24.6 million, compared with $47.8 million as of December 31, 2013.

Business Highlights
  • Announced NeuVax (nelipepimut-S) Phase 3 PRESENT Trial enrollment status. Galena provided the current enrollment status for the Company's Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment) clinical trial. As of September 22, 2014, 533 of the 700 patients required by the clinical trial protocol had been treated. The Company expects to treat 700 patients by the end of January 2015 with the intention to over-enroll the study, targeting the end of Q1, 2015 to close enrollment.  
  • Significantly Expanded the NeuVax Intellectual Property Position with Notice of Allowances for Three Important Patents
    • Patent will cover the use of NeuVax to prevent recurrence of any HER2/neu expressing tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0 as a stand-alone therapy or in combination with an adjuvant and/or other agents. Currently there are no approved HER2-directed therapies for patients who express lower levels of HER2, or less than 2.0 by the FISH testing scale. Importantly, this NeuVax patent provides Galena with coverage for any tumor expressing low-to-intermediate levels of HER2.  The patent, which has now issued, will expire in 2028, not including any patent term extensions.
    • Patent To Cover the Use of NeuVax in Combination With Herceptin® (trastuzumab; Genentech/Roche) for treating patients having any HER2/neu expressing cancer. The allowed claims of this patent will cover all HER2/neu expressing cancer types and patient populations. Once issued, the patent will expire in 2026, not including any patent term extensions.
    • Improvement patent in Japan will cover the use of NeuVax alone or in combination with other agents to prevent recurrence of any breast cancer tumor expressing low-to-intermediate (Immunohistochemistry (IHC) 1+ or 2+ or FISH less than about 2.0) levels of HER2. Once issued, the patent will expire in 2027, not including any patent term extensions.  
  • Initiated the Phase 2 Clinical Trial for GALE-401 (Anagrelide Controlled Release). The study will treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET). The Phase 2 trial is an open-label, single-arm, multicenter study of GALE-401 in approximately 20 patients with MPN-related thrombocytosis. The goals of the study are to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure blood levels of the drug. The primary efficacy endpoint will be the proportion of subjects who achieve a complete or partial platelet response for at least four weeks during the first six months of treatment. Based on discussions with the U.S. Food and Drug Administration (FDA) and pending a successful development program, Galena would pursue approval via the 505(b)(2) regulatory pathway.  
  • Appointed Mark W. Schwartz, PhD as President and Chief Executive Officer and member of the Board of Directors. Dr. Schwartz was previously Galena's Executive Vice President and Chief Operating Officer where he worked across all of the company's programs, oversaw the initiation of the commercialization efforts, and also managed intellectual property efforts, acquisitions, and partnerships. Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry and joined the Company following Galena's acquisition of Apthera, Inc. where he served as the company's President and CEO. Prior to Apthera, Dr. Schwartz served as President and CEO of Bayhill Therapeutics where he completed a successful partnership with Genentech around one of its compounds. Previously, he served as President and CEO of Calyx Therapeutics. Earlier in his career, Dr. Schwartz held a range of positions in R&D, marketing, sales, business development and executive management at Trega BioSciences, Incyte Genomics, Synteni, Tripos, Applied Biosystems and DuPont Diagnostics. Dr. Schwartz is currently on the advisory board for BayBio, a Director of Targazyme Pharmaceuticals, and is on the faculty of San Jose State University in the Masters of Biotechnology Program. He is also a former Board member of the Biotechnology Industry Association. Dr. Schwartz received his Bachelor of Arts in Chemistry from Grinnell College and his Ph.D. in Chemistry from Arizona State University.  
  • Licensed the U.S. Rights for Zuplenz® (ondansetron) Oral Soluble Film. Zuplenz is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV).  Zuplenz is also approved in pediatric patients for moderately emetogenic CINV. Zuplenz is a rapidly dissolving, oral soluble film that dissolves on the tongue in less than thirty seconds and eliminates the burden of swallowing pills during periods of emesis and in cases of oral irritation, potentially increasing patient adherence. Galena expects to launch Zuplenz in the first quarter 2015.
(Amounts in thousands, except share and per share data)
  Three Months Ended September 30, Nine Months Ended September 30,
  2014 2013 2014 2013
Net revenue  $ 1,620  $ 1,170  $ 6,124  $ 1,170
Costs and expenses:        
Cost of revenue (excluding amortization of certain acquired intangible assets) 247 258 925 258
Research and development 7,243 3,633 22,082 13,990
Selling, general, and administrative 7,268 4,129 23,698 8,369
Amortization of certain acquired intangible assets 70 43 259 43
Total costs and expenses 14,828 8,063 46,964 22,660
Operating loss (13,208) (6,893) (40,840) (21,490)
Non-operating income (expense):        
Change in fair value of warrants potentially settleable in cash 6,735 (1,614) 13,174 (7,135)
Interest income (expense), net (297) (314) (925) (495)
Other income (expense) 597 693 (59) 881
Total non-operating income (expense), net 7,035 (1,235) 12,190 (6,749)
Loss before income taxes (6,173) (8,128) (28,650) (28,239)
Income tax benefit 1,159 (62)
Net loss  $ (6,173)  $ (9,287)  $ (28,650)  $ (28,177)
Net loss per common share:        
Basic and diluted net loss per share  $ (0.05)  $ (0.11)  $ (0.24)  $ (0.33)
Weighted-average common shares outstanding: basic and diluted 119,038,656 87,319,450 117,767,791 84,678,612
(Amounts in thousands)
  September 30, 2014 (Unaudited) December 31, 2013
Current assets:    
Cash and cash equivalents  $ 24,647  $ 47,787
Restricted cash 200 200
Accounts receivable 1,435 3,683
Inventories 450 386
Prepaid expenses 1,789 1,399
Total current assets 28,521 53,455
Equipment and furnishings, net 589 665
In-process research and development 12,864 12,864
Abstral rights, net 14,714 14,979
Zuplenz rights 7,663
GALE-401 rights 9,155
Goodwill 5,898 5,898
Deposits and other assets 88 115
Total assets  $ 79,492  $ 87,976
Current liabilities:    
Accounts payable  $ 3,360  $ 2,660
Accrued expenses and other current liabilities 15,292 8,667
Current maturities of capital lease obligations 6 6
Fair value of warrants potentially settleable in cash 8,765 48,965
Current portion of long-term debt 4,163 2,149
Total current liabilities 31,586 62,447
Capital lease obligations, net of current maturities 17 26
Deferred tax liability 5,053 5,053
Contingent purchase price consideration, net of current portion 6,880 6,821
Long-term debt, net of current portion 5,097 7,743
Total liabilities 48,633 82,090
Total stockholders' equity 30,859 5,886
Total liabilities and stockholders' equity  $ 79,492  $ 87,976

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care.  Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral ® (fentanyl) Sublingual Tablets and Zuplenz ® (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information visit www.galenabiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our 2014 revenue from the sale of Abstral®, our planned launch of Zuplenz®, the issuance of patents, and the progress of development of Galena's product candidates, including patient enrollment in our clinical trials. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended December 31, 2013 and most recent Quarterly Reports on Form 10-Q filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

NeuVax is a trademark of Galena Biopharma, Inc. All other trademarks are the property of their respective owners.
CONTACT: Remy Bernarda         VP, Marketing & Communications         (503) 405-8258         rbernarda@galenabiopharma.com

Galena Biopharma, Inc.